Trade Cumberland - CPIX CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.1084 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Prev. Close* | 1.7358 |
Open* | 1.6358 |
1-Year Change* | -14.67% |
Day's Range* | 1.6358 - 1.8558 |
52 wk Range | 1.43-2.79 |
Average Volume (10 days) | 18.81K |
Average Volume (3 months) | 275.60K |
Market Cap | 27.51M |
P/E Ratio | -100.00K |
Shares Outstanding | 14.26M |
Revenue | 39.32M |
EPS | -0.17 |
Dividend (Yield %) | N/A |
Beta | 0.17 |
Next Earnings Date | Mar 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 1.7358 | 0.0400 | 2.36% | 1.6958 | 1.7858 | 1.6358 |
Mar 26, 2024 | 1.6958 | 0.0400 | 2.42% | 1.6558 | 1.8158 | 1.6558 |
Mar 25, 2024 | 1.7058 | -0.0400 | -2.29% | 1.7458 | 1.7858 | 1.7058 |
Mar 22, 2024 | 1.7758 | -0.0300 | -1.66% | 1.8058 | 1.8158 | 1.7458 |
Mar 21, 2024 | 1.7958 | -0.0100 | -0.55% | 1.8058 | 1.8758 | 1.7658 |
Mar 20, 2024 | 1.8058 | 0.0300 | 1.69% | 1.7758 | 1.8858 | 1.7658 |
Mar 19, 2024 | 1.8158 | -0.2200 | -10.81% | 2.0358 | 2.0358 | 1.7658 |
Mar 18, 2024 | 1.8658 | 0.1000 | 5.66% | 1.7658 | 1.9258 | 1.7658 |
Mar 15, 2024 | 1.7958 | -0.0200 | -1.10% | 1.8158 | 1.9758 | 1.7658 |
Mar 14, 2024 | 1.7958 | -0.0200 | -1.10% | 1.8158 | 1.8858 | 1.7958 |
Mar 13, 2024 | 1.7958 | -0.0100 | -0.55% | 1.8058 | 1.8958 | 1.7958 |
Mar 12, 2024 | 1.8058 | -0.1000 | -5.25% | 1.9058 | 1.9958 | 1.8058 |
Mar 11, 2024 | 1.9958 | -0.0100 | -0.50% | 2.0058 | 2.0258 | 1.9558 |
Mar 8, 2024 | 2.0058 | 0.0000 | 0.00% | 2.0058 | 2.0758 | 1.9958 |
Mar 7, 2024 | 2.0158 | 0.0000 | 0.00% | 2.0158 | 2.0558 | 1.9958 |
Mar 6, 2024 | 1.9358 | 0.0200 | 1.04% | 1.9158 | 1.9958 | 1.7958 |
Mar 5, 2024 | 1.9958 | -0.0200 | -0.99% | 2.0158 | 2.0958 | 1.9058 |
Mar 4, 2024 | 2.0258 | 0.0200 | 1.00% | 2.0058 | 2.1558 | 1.9658 |
Mar 1, 2024 | 2.1158 | -0.0200 | -0.94% | 2.1358 | 2.1958 | 2.0258 |
Feb 29, 2024 | 2.1258 | 0.0000 | 0.00% | 2.1258 | 2.1558 | 2.1258 |
Cumberland Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, April 24, 2024 | ||
Time (UTC) 14:30 | Country US
| Event Cumberland Pharmaceuticals Inc Annual Shareholders Meeting Cumberland Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Tuesday, May 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Cumberland Pharmaceuticals Inc Earnings Release Q1 2024 Cumberland Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 42.0109 | 35.985 | 37.4411 | 34.3883 | 29.3449 |
Revenue | 42.0109 | 35.985 | 37.4411 | 34.3883 | 29.3449 |
Cost of Revenue, Total | 9.11852 | 7.41125 | 8.45302 | 7.42132 | 6.01682 |
Gross Profit | 32.8924 | 28.5738 | 28.9881 | 26.967 | 23.3281 |
Total Operating Expense | 47.7159 | 43.6625 | 43.8227 | 43.6765 | 40.5179 |
Selling/General/Admin. Expenses, Total | 26.5803 | 24.5604 | 24.9618 | 25.2521 | 24.1557 |
Research & Development | 6.68892 | 5.68447 | 5.77383 | 6.86848 | 7.57589 |
Depreciation / Amortization | 5.32811 | 4.60637 | 4.43412 | 4.13456 | 2.76947 |
Operating Income | -5.70493 | -7.67742 | -6.3816 | -9.28818 | -11.173 |
Interest Income (Expense), Net Non-Operating | -0.48759 | -0.07195 | -0.18828 | -0.00283 | 0.36863 |
Net Income Before Taxes | -5.58119 | -5.56223 | -6.56988 | -9.291 | -10.8044 |
Net Income After Taxes | -5.65004 | -5.59712 | -6.62578 | -9.21169 | -10.821 |
Minority Interest | 0.0798 | 0.09521 | 0.0795 | 0.00875 | 0.0757 |
Net Income Before Extra. Items | -5.57024 | -5.50191 | -6.54628 | -9.20294 | -10.7453 |
Net Income | -5.57024 | -3.50759 | -3.33941 | -3.53776 | -6.96307 |
Income Available to Common Excl. Extra. Items | -5.57024 | -5.50191 | -6.54628 | -9.20294 | -10.7453 |
Income Available to Common Incl. Extra. Items | -5.57024 | -3.50759 | -3.33941 | -3.53776 | -6.96307 |
Diluted Net Income | -5.57024 | -3.50759 | -3.33941 | -3.53776 | -6.96307 |
Diluted Weighted Average Shares | 14.5636 | 14.9048 | 15.1622 | 15.3961 | 15.614 |
Diluted EPS Excluding Extraordinary Items | -0.38248 | -0.36914 | -0.43175 | -0.59774 | -0.68818 |
Diluted Normalized EPS | -0.38248 | -0.30808 | -0.42318 | -0.59774 | -0.68818 |
Total Extraordinary Items | 0 | 1.99432 | 3.20688 | 5.66518 | 3.78222 |
Unusual Expense (Income) | 0 | 1.4 | 0.2 | 0 | |
Other, Net | 0.61133 | 2.18714 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 10.8889 | 9.22464 | 9.12368 | 11.4131 | 10.2992 |
Revenue | 10.8889 | 9.22464 | 9.12368 | 11.4131 | 10.2992 |
Cost of Revenue, Total | 1.52077 | 1.25026 | 4.45031 | 1.42444 | 1.63188 |
Gross Profit | 9.36811 | 7.97438 | 4.67337 | 9.98863 | 8.66727 |
Total Operating Expense | 10.866 | 10.7563 | 11.4015 | 11.7017 | 12.1457 |
Selling/General/Admin. Expenses, Total | 7.04196 | 6.77631 | 6.88711 | 6.27652 | 6.76066 |
Research & Development | 1.14504 | 1.49967 | 1.40584 | 1.71425 | 1.82369 |
Depreciation / Amortization | 1.15825 | 1.23007 | 0.45822 | 1.48645 | 1.52945 |
Unusual Expense (Income) | -1.8 | 0.8 | 0.4 | ||
Operating Income | 0.02286 | -1.53168 | -2.2778 | -0.28859 | -1.84654 |
Interest Income (Expense), Net Non-Operating | -0.13558 | -0.13616 | -0.13376 | -0.12774 | -0.12255 |
Net Income Before Taxes | 0.86909 | 0.17922 | -2.41156 | -0.41633 | -1.35777 |
Net Income After Taxes | 0.86215 | 0.17229 | -2.45971 | -0.42323 | -1.36467 |
Minority Interest | 0.01005 | 0.0199 | 0.01899 | 0.01459 | 0.02905 |
Net Income Before Extra. Items | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Total Extraordinary Items | 0 | 0 | 0 | ||
Net Income | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Income Available to Common Excl. Extra. Items | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Income Available to Common Incl. Extra. Items | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Diluted Net Income | 0.8722 | 0.19218 | -2.44073 | -0.40864 | -1.33562 |
Diluted Weighted Average Shares | 14.5543 | 14.5878 | 14.3974 | 14.4775 | 14.6885 |
Diluted EPS Excluding Extraordinary Items | 0.05993 | 0.01317 | -0.16953 | -0.02823 | -0.09093 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.05993 | 0.01317 | -0.25079 | 0.00769 | -0.07323 |
Other, Net | 0.98181 | 1.84707 | 0 | 0 | 0.61133 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 45.8702 | 45.688 | 49.9696 | 50.1631 | 59.116 |
Cash and Short Term Investments | 19.758 | 27.0408 | 24.7538 | 28.2126 | 36.2296 |
Cash & Equivalents | 19.758 | 27.0408 | 24.7538 | 28.2126 | 27.939 |
Short Term Investments | 0 | 8.29068 | |||
Total Receivables, Net | 13.1637 | 6.87735 | 12.3777 | 9.78146 | 7.84425 |
Accounts Receivable - Trade, Net | 13.1637 | 6.87735 | 12.3777 | 9.78146 | 7.84425 |
Total Inventory | 9.86358 | 8.42988 | 10.6382 | 9.41152 | 12.0783 |
Prepaid Expenses | 3.08498 | 3.33997 | 2.19993 | 2.75746 | 2.96381 |
Total Assets | 92.9252 | 84.4598 | 96.4633 | 104.549 | 112.694 |
Property/Plant/Equipment, Total - Net | 5.50244 | 1.46684 | 2.60232 | 3.70837 | 0.77121 |
Property/Plant/Equipment, Total - Gross | 7.58763 | 5.25899 | 6.1594 | 7.10269 | 3.89592 |
Accumulated Depreciation, Total | -2.08519 | -3.79215 | -3.55709 | -3.39433 | -3.12471 |
Intangibles, Net | 30.5907 | 23.9545 | 28.1183 | 30.9203 | 33.6551 |
Other Long Term Assets, Total | 10.0478 | 12.4685 | 14.8911 | 18.8755 | 18.3675 |
Total Current Liabilities | 28.5798 | 19.279 | 25.6674 | 24.1502 | 27.8042 |
Accounts Payable | 10.819 | 9.64098 | 13.3963 | 11.9124 | 11.0933 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.5374 | 7.30925 | 9.96232 | 9.19241 | 15.0131 |
Total Liabilities | 56.659 | 41.6455 | 49.4728 | 53.4264 | 56.8491 |
Total Long Term Debt | 16.2 | 15 | 15 | 18.5 | 20 |
Long Term Debt | 16.2 | 15 | 15 | 18.5 | 20 |
Minority Interest | -0.29213 | -0.21233 | -0.11712 | -0.03762 | -0.27427 |
Other Liabilities, Total | 12.1713 | 7.57886 | 8.92247 | 10.8138 | 9.31914 |
Total Equity | 36.2661 | 42.8143 | 46.9905 | 51.1229 | 55.8448 |
Common Stock | 47.475 | 48.4529 | 49.1215 | 49.9145 | 51.0986 |
Retained Earnings (Accumulated Deficit) | -11.2088 | -5.6386 | -2.13101 | 1.2084 | 4.74615 |
Total Liabilities & Shareholders’ Equity | 92.9252 | 84.4598 | 96.4633 | 104.549 | 112.694 |
Total Common Shares Outstanding | 14.3663 | 14.7428 | 14.9884 | 15.2636 | 15.4815 |
Goodwill, Net | 0.914 | 0.882 | 0.882 | 0.882 | 0.784 |
Accrued Expenses | 2.22339 | 2.32873 | 2.30884 | 3.04538 | 1.69783 |
Other Current Assets, Total | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 41.7698 | 43.6741 | 43.8108 | 45.8702 | 49.1606 |
Cash and Short Term Investments | 18.508 | 18.2491 | 16.3862 | 19.758 | 19.5415 |
Cash & Equivalents | 18.508 | 18.2491 | 16.3862 | 19.758 | 19.5415 |
Total Receivables, Net | 12.6201 | 12.2188 | 14.5291 | 13.1637 | 15.2327 |
Accounts Receivable - Trade, Net | 12.6201 | 12.2188 | 14.5291 | 13.1637 | 15.2327 |
Total Inventory | 8.67055 | 10.9284 | 10.18 | 9.86358 | 10.6475 |
Prepaid Expenses | 1.97116 | 2.27789 | 2.7155 | 3.08498 | 3.73884 |
Total Assets | 87.7509 | 89.3754 | 89.4686 | 92.9252 | 90.7766 |
Property/Plant/Equipment, Total - Net | 7.08859 | 7.21589 | 5.27391 | 5.50244 | 0.71068 |
Goodwill, Net | 0.914 | 0.914 | 0.914 | 0.914 | 1.93288 |
Intangibles, Net | 27.1211 | 28.2698 | 29.3902 | 30.5907 | 29.048 |
Other Long Term Assets, Total | 10.8575 | 9.30156 | 10.0797 | 10.0478 | 9.92435 |
Total Current Liabilities | 27.3283 | 26.9591 | 25.7074 | 28.5798 | 25.3062 |
Accounts Payable | 10.8181 | 10.912 | 11.2223 | 10.819 | 11.5108 |
Accrued Expenses | 0.33429 | 0.32084 | 0.15837 | 0.17291 | 0.22961 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 16.1759 | 15.7262 | 14.3267 | 17.5879 | 13.5659 |
Total Liabilities | 51.7594 | 52.2164 | 53.1081 | 56.659 | 52.0123 |
Total Long Term Debt | 12.9231 | 13.1481 | 16.0723 | 16.2 | 17.7 |
Long Term Debt | 12.9231 | 13.1481 | 16.0723 | 16.2 | 17.7 |
Minority Interest | -0.33599 | -0.32207 | -0.31202 | -0.29213 | -0.27314 |
Other Liabilities, Total | 11.844 | 12.4312 | 11.6404 | 12.1713 | 9.27921 |
Total Equity | 35.9916 | 37.159 | 36.3605 | 36.2661 | 38.7643 |
Common Stock | 47.1853 | 47.3034 | 47.3772 | 47.475 | 47.5324 |
Retained Earnings (Accumulated Deficit) | -11.1938 | -10.1445 | -11.0167 | -11.2088 | -8.76811 |
Total Liabilities & Shareholders’ Equity | 87.7509 | 89.3754 | 89.4686 | 92.9252 | 90.7766 |
Total Common Shares Outstanding | 14.2179 | 14.331 | 14.43 | 14.3663 | 14.4366 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -5.65004 | -3.6028 | -3.4189 | -3.54651 | -7.03877 |
Cash From Operating Activities | 8.4534 | 6.34244 | 5.41506 | 3.05636 | 3.11274 |
Cash From Operating Activities | 5.32811 | 4.60637 | 4.74857 | 4.40418 | 2.9827 |
Deferred Taxes | 0 | 0 | 0.0218 | 0.06541 | 0.08189 |
Non-Cash Items | -1.66511 | -2.84118 | 0.5308 | 0.70294 | 1.21426 |
Cash Taxes Paid | 0.0033 | -0.00033 | -0.09149 | 0.01669 | 0.01544 |
Cash Interest Paid | 0.52316 | 0.06398 | 0.21599 | 0.19866 | 0.09597 |
Changes in Working Capital | 10.4404 | 8.18005 | 3.5328 | 1.43034 | 5.87267 |
Cash From Investing Activities | -13.6745 | -0.50189 | -1.75779 | 2.29785 | -27.7248 |
Capital Expenditures | -2.07381 | -0.35446 | -2.11393 | -1.01915 | -4.27506 |
Other Investing Cash Flow Items, Total | -11.6006 | -0.14743 | 0.35614 | 3.31699 | -23.4498 |
Cash From Financing Activities | -2.06179 | -3.55353 | -7.11611 | -5.08053 | 7.13817 |
Financing Cash Flow Items | -2.20874 | -2.16668 | -1.76459 | -0.08561 | -0.38331 |
Issuance (Retirement) of Stock, Net | -1.05304 | -1.38685 | -1.85153 | -3.49492 | -2.67852 |
Issuance (Retirement) of Debt, Net | 1.2 | 0 | -3.5 | -1.5 | 10.2 |
Net Change in Cash | -7.28285 | 2.28702 | -3.45884 | 0.27368 | -17.4739 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 0.17229 | -5.65004 | -3.19033 | -2.7671 | -1.40243 |
Cash From Operating Activities | -1.41821 | 8.4534 | 4.81537 | 2.18004 | -0.1505 |
Cash From Operating Activities | 1.25568 | 5.32811 | 4.81663 | 3.27209 | 1.65375 |
Non-Cash Items | -2.05105 | -1.66511 | -0.62674 | 0.05563 | 0.75476 |
Changes in Working Capital | -0.79512 | 10.4404 | 3.8158 | 1.61942 | -1.15657 |
Cash From Investing Activities | -0.17445 | -13.6745 | -13.0337 | -13.7145 | -13.5419 |
Capital Expenditures | -0.17445 | -2.07381 | -0.43304 | -0.21449 | -0.0419 |
Other Investing Cash Flow Items, Total | 0 | -11.6006 | -12.6006 | -13.5 | -13.5 |
Cash From Financing Activities | -1.77914 | -2.06179 | 0.71904 | 2.7102 | 3.91837 |
Financing Cash Flow Items | -1.46431 | -2.20874 | -1.11758 | -0.50151 | -0.50151 |
Issuance (Retirement) of Stock, Net | -0.18712 | -1.05304 | -0.86338 | -0.7883 | -0.58013 |
Issuance (Retirement) of Debt, Net | -0.12771 | 1.2 | 2.7 | 4 | 5 |
Net Change in Cash | -3.3718 | -7.28285 | -7.49928 | -8.82425 | -9.77403 |
Deferred Taxes | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Cumberland Company profile
About Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription products. The Company's product portfolio includes Acetadote (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection, for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and RediTrex.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cumberland Pharmaceuticals, Inc. revenues decreased 4% to $36M. Net loss before extraordinary items decreased 16% to $5.5M. Revenues reflect Acetadote segment decrease of 55% to $851K, RediTrex segment decrease of 94% to $55K. Lower net loss reflects Interest expense decrease of 63% to $98K (expense), Research and Development decrease of 2% to $5.7M (expense).
Equity composition
Common stock no par, 03/11, 100M auth., 20,432,034 issd. Insider owns approx. 37.85% .IPO:8/11/2009, 5M shares @ $17 per share by UBS Securities LLC, Jefferies & Company, Inc., Wells Fargo Securities, LLC & MorganJoseph & Co. Inc. 6/07,Stock Split 2:1.
Industry: | Generic Pharmaceuticals |
2525 W End Ave Ste 950
NASHVILLE
TENNESSEE 37203-1608
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com